We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

SAMBA EU Femoropopliteal Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01139177
Recruitment Status : Unknown
Verified June 2010 by NovoStent Corporation.
Recruitment status was:  Active, not recruiting
First Posted : June 8, 2010
Last Update Posted : June 8, 2010
Information provided by:
NovoStent Corporation

Brief Summary:
The primary objective of this study is to evaluate the safety and performance of the SAMBA Stent and Delivery System in the treatment of femoropopliteal lesions.

Condition or disease Intervention/treatment Phase
Peripheral Vascular Disease Device: Stenting of atherosclerotic lesion(s) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: SAMBA EU Femoropopliteal Trial
Study Start Date : April 2009
Estimated Primary Completion Date : September 2010
Estimated Study Completion Date : September 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Stent placement Device: Stenting of atherosclerotic lesion(s)
Stenting of atherosclerotic lesions post pre-dilatation of lesion(s)
Other Name: SAMBA Stent and Delivery System

Primary Outcome Measures :
  1. The primary safety endpoint is defined as freedom from all cause death, unplanned index limb amputation, and target lesion revascularization. [ Time Frame: through 30 days ]
  2. The primary efficacy endpoint is defined as stent patency via Color Duplex Ultrasound (Peak Velocity Ratio ≤ 2.5). [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. Clinically-Driven Target Lesion Revascularization (i.e., with documented preintervention evidence of at least 50% diameter stenosis (quantitative angiographic ≥ 50% or PSVR > 2.5). [ Time Frame: 12 months ]
  2. Change in Rutherford Classification compared to pre-implant. [ Time Frame: 12 months ]
  3. Stent Patency via Color Duplex Ultrasound (Peak Systolic Velocity Ratio ≤ 2.5). [ Time Frame: 12 months ]
  4. Stent Fractures. [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:


  1. Patient must be ≥ 21 years of age with life expectancy > 1 year.
  2. Symptomatic leg ischemia requiring treatment of the superficial femoral and/or popliteal artery (Rutherford category 2-4; claudication, rest pain).
  3. Patient must be a suitable candidate for PTA and stenting.
  4. Patient is willing and able to return to the site of the investigation at the specified study intervals and undergo follow-up requirements.
  5. The patient or legal representative has provided written informed consent using a form that is reviewed and approved by the EC for the Clinical Site.


  1. Target lesion has ≥ 50% stenosis as demonstrated angiographically.
  2. Lesion length ≤ 15 cm.
  3. Reference vessel diameter of 5 to 6 mm.
  4. Patient has at least 1 vessel run-off prior to treatment.

Exclusion Criteria:


  1. The subject is pregnant or will become pregnant during the study or has any other condition that would preclude having x-rays. (Pre-menopausal women must have a negative pregnancy test within 7 days of the procedure.)
  2. Patients who have experienced a cardiovascular accident (CVA) or a myocardial infarction (MI) within 3 months prior to the procedure.
  3. Subject has had or plans to have a surgical or interventional procedure within 30 days before or after the implantation procedure of the SAMBA Stent.
  4. Existing hemorrhagic disease or coagulation problems or inability to take dual anti-platelet therapy.
  5. Contrast allergy that cannot be corrected with medication (e.g. steroids, etc.).
  6. Subject has other medical, social, or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment and the procedures and evaluations pre- and post-treatment.
  7. Patient is currently participating in another investigational drug or device study.


  1. Uncorrectable severe aorto-iliac occlusive disease or severe common femoral artery stenosis preventing access or limiting inflow (e.g., stenosis greater than 50%).
  2. Uncorrectable occlusive disease limiting outflow (e.g., stenosis greater than 50%)
  3. Patients with previous surgery in the target vessel or stent that will be closer than 2 cm to either edge of SAMBA Stent(s).
  4. Lack of 1 cm of healthy vessel proximal to proximal target
  5. Lack of popliteal reconstitution (at least 2 cm of normal distal popliteal).
  6. Inability to cross the lesion with a guidewire.
  7. More than 1 lesion in the same limb requiring treatment that will not be covered by continuous stenting.
  8. Unsuccessful balloon pre-dilation (i.e., the residual stenosis is greater than 30%).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01139177

Layout table for location information
Herz Zentrum Bad Krozingen
Bad Krozingen, Germany, D 79189
Herz-Zentrum Leipzig
Leipzig, Germany, D-04289
Sponsors and Collaborators
NovoStent Corporation
Layout table for investigator information
Principal Investigator: Dierk Scheinert, MD Herz-Zentrum Leipzig
Layout table for additonal information
Responsible Party: Earle Canty, VP RACAQA, NovoStent Corporation
ClinicalTrials.gov Identifier: NCT01139177    
Other Study ID Numbers: 60-00857-01
First Posted: June 8, 2010    Key Record Dates
Last Update Posted: June 8, 2010
Last Verified: June 2010
Keywords provided by NovoStent Corporation:
Peripheral vascular disease - SFA and popliteal arteries.
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Peripheral Vascular Diseases
Peripheral Arterial Disease
Cardiovascular Diseases
Arterial Occlusive Diseases